Alcobra Discusses Path to Resume MDX Trials With FDA

Alcobra held a “productive” face-to-face meeting with the Division of Psychiatry Products (DPP) of the U.S. Food and Drug Administration to discuss the FDA’s decision to place a full clinical hold on the development programs of metadoxine extended release (MDX), and paths to resume human clinical trials with MDX.

The company expects to provide further details regarding the MDX regulatory path upon receipt of final meeting minutes from the DPP in the coming weeks.

Shares of Alcobra, a pharmaceutical company which focuses on the development of medications to treat cognitive disorders, are trading nearly 5% higher in premarket.

Leave a Comment